Facile Therapeutics
Matthew Bogyo is a co-founder and the head of the scientific advisory board at Facile Therapeutics. Matthew was previously the group leader and head of chemical proteomics at Celera Genomics, and before that, they were a faculty fellow at the University of California, San Francisco. Bogyo received their undergraduate degree from Stanford University and their PhD from the University of California, Berkeley.
Matthew Bogyo has a PhD in Biochemistry from the Massachusetts Institute of Technology and a BS in Chemistry from Bates College.
This person is not in the org chart
This person is not in any offices
Facile Therapeutics
Facile Therapeutics is bringing Ebselen into the clinic to demonstrate it will be effective in preventing the recurrence of CDI in a Proof-of-Concept (PoC) clinical trial.